Eli Lilly Company: Atomoxetine米国添付文書 (http://www.fda.gov/CDER/foi/label/2002/021411lbl.pdf)
Banaschewski, T., Coghill, D., Santosh, P. et al.: Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur. Child Adolesc. Psychiatry, 15: 476-495, 2006.
Bangs, M. E., Tauscher-Wisniewski, S., Polzer, J. et al.: Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J. Am. Acad. Child Adolesc. Psychiatry, 47: 209-218, 2008.
Bangs, M. E., Jin, L., Zhang, S. et al.: Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf., 31: 345-354, 2008.
Barkley, R. A.: Attention-deficit/hyperactivity disorder, self-regulation, and time: toward a more comprehensive theory. J. Dev. Behav. Pediatr., 18: 271-279, 1997.